Sanara MedTech Inc. (SMTI) 10-Year Financial Performance & Capital Metrics

SMTI • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesAdvanced Wound Care

AboutSanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Show more

Revenue $87M +33.4%
EBITDA -$2M -231.8%
Net Income -$10M -124.6%
EPS (Diluted) -1.14 -119.2%
Gross Margin 90.61% +3.1%
EBITDA Margin -2.07% -148.8%
Operating Margin -7.75% -19.5%
Net Margin -11.15% -68.4%
ROE -23.15% -132.1%
ROIC -9.45% -26.8%
Debt/Equity 0.83 +213.7%
Interest Coverage -2.15 +75.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 49.1%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y41.82%

5Y49.09%

3Y53.12%

TTM30.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-348.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM26.1%

ROCE

10Y Avg-52.43%

5Y Avg-31.64%

3Y Avg-16.58%

Latest-10.11%

Peer Comparison

Advanced Wound Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
NEPHNephros, Inc.	46.54M	4.38	625.71	-0.53%	8.26%	14.8%	0.16
NXGLNEXGEL, Inc.	14.17M	1.74	-3.48	112.47%	-24.69%	-51.65%	0.46
SMTISanara MedTech Inc.	212.4M	23.77	-20.85	33.36%	-36.79%	-6.11%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.37M	5.51M	6.3M	5.84M	11.77M	15.59M	24.14M	45.84M	64.99M	86.67M
Revenue Growth %	0.28%	0.63%	0.14%	-0.07%	1.02%	0.32%	0.55%	0.9%	0.42%	0.33%
Cost of Goods Sold+	891.97K	943.58K	806.04K	507.42K	1.21M	1.62M	2.31M	6.36M	7.85M	8.14M
COGS % of Revenue	0.26%	0.17%	0.13%	0.09%	0.1%	0.1%	0.1%	0.14%	0.12%	0.09%
Gross Profit+	2.48M	4.56M	5.5M	5.33M	10.56M	13.97M	21.83M	39.48M	57.14M	78.53M
Gross Margin %	0.74%	0.83%	0.87%	0.91%	0.9%	0.9%	0.9%	0.86%	0.88%	0.91%
Gross Profit Growth %	0.36%	0.84%	0.2%	-0.03%	0.98%	0.32%	0.56%	0.81%	0.45%	0.37%
Operating Expenses+	3.45M	4.84M	5.36M	5.82M	13.3M	19M	29.21M	52M	61.35M	85.25M
OpEx % of Revenue	1.02%	0.88%	0.85%	1%	1.13%	1.22%	1.21%	1.13%	0.94%	0.98%
Selling, General & Admin	3.39M	4.76M	5.28M	5.74M	13.07M	18.67M	28.05M	45.98M	56.99M	76.56M
SG&A % of Revenue	1%	0.87%	0.84%	0.98%	1.11%	1.2%	1.16%	1%	0.88%	0.88%
Research & Development	0	0	0	0	0	40.19K	558.7K	3.37M	4.13M	5.7M
R&D % of Revenue	-	-	-	-	-	0%	0.02%	0.07%	0.06%	0.07%
Other Operating Expenses	60.03K	21	125	-22.08K	229.95K	291.37K	596.98K	2.66M	225.13K	2.98M
Operating Income+	-964.98K	-272.13K	120.44K	-501.86K	-2.74M	-5.03M	-7.38M	-12.52M	-4.22M	-6.72M
Operating Margin %	-0.29%	-0.05%	0.02%	-0.09%	-0.23%	-0.32%	-0.31%	-0.27%	-0.06%	-0.08%
Operating Income Growth %	0.53%	0.72%	1.44%	-5.17%	-4.46%	-0.84%	-0.47%	-0.7%	0.66%	-0.59%
EBITDA+	-904.95K	-211.25K	201.09K	-444.92K	-2.62M	-4.74M	-6.6M	-10.15M	-540.13K	-1.79M
EBITDA Margin %	-0.27%	-0.04%	0.03%	-0.08%	-0.22%	-0.3%	-0.27%	-0.22%	-0.01%	-0.02%
EBITDA Growth %	0.55%	0.77%	1.95%	-3.21%	-4.89%	-0.81%	-0.39%	-0.54%	0.95%	-2.32%
D&A (Non-Cash Add-back)	60.03K	60.88K	80.65K	56.94K	119.95K	291.37K	771.93K	2.37M	3.68M	4.92M
EBIT	-1.16M	-241.25K	458.13K	-513.99K	-2.73M	-4.43M	-7.99M	-13.94M	-3.96M	-6.78M
Net Interest Income+	-176.89K	-174.49K	-126.83K	-86.59K	-105.92K	-11.53K	-711	0	-475.78K	-3.11M
Interest Income	0	0	0	0	0	0	0	284.75K	0	21.98K
Interest Expense	176.89K	174.49K	126.83K	86.59K	105.92K	11.53K	711	284.75K	475.78K	3.13M
Other Income/Expense	-375.47K	-143.61K	210.87K	-98.71K	-95.72K	589.47K	-617.64K	-1.42M	-224.75K	-3.2M
Pretax Income+	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-13.94M	-4.44M	-9.91M
Pretax Margin %	-0.4%	-0.08%	0.05%	-0.1%	-0.24%	-0.29%	-0.33%	-0.3%	-0.07%	-0.11%
Income Tax+	0	0	0	0	0	0	0	-5.84M	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.99%	0.98%	0.99%	0.57%	0.97%	0.98%
Net Income+	-1.34M	-415.75K	331.31K	-600.57K	-2.81M	-4.36M	-7.92M	-7.94M	-4.3M	-9.66M
Net Margin %	-0.4%	-0.08%	0.05%	-0.1%	-0.24%	-0.28%	-0.33%	-0.17%	-0.07%	-0.11%
Net Income Growth %	0.41%	0.69%	1.8%	-2.81%	-3.69%	-0.55%	-0.82%	-0%	0.46%	-1.25%
Net Income (Continuing)	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-8.09M	-4.44M	-9.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	-221.69K	-310.39K	-488.4K	-107.56K	-244.26K	-491.61K
EPS (Diluted)+	-1.25	-0.38	0.09	-0.28	-1.37	-0.76	-1.08	-1.00	-0.52	-1.14
EPS Growth %	0.42%	0.7%	1.24%	-4.04%	-3.89%	0.45%	-0.42%	0.07%	0.48%	-1.19%
EPS (Basic)	-1.26	-0.38	0.17	-0.28	-1.37	-0.76	-1.08	-1.00	-0.52	-1.14
Diluted Shares Outstanding	1.07M	1.1M	2.09M	2.17M	2.13M	5.73M	7.34M	7.91M	8.28M	8.48M
Basic Shares Outstanding	1.07M	1.09M	1.11M	2.17M	2.13M	5.73M	7.34M	7.91M	8.28M	8.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.16M	2M	2.04M	978.48K	8.86M	4.48M	24.61M	20.62M	19.01M	33.31M
Cash & Short-Term Investments	182.34K	833.48K	463.19K	731.85K	6.61M	455.37K	18.65M	8.96M	5.15M	15.88M
Cash Only	182.34K	833.48K	463.19K	731.85K	6.61M	455.37K	18.65M	8.96M	5.15M	15.88M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	452.55K	794.29K	836.5K	164.46K	1.34M	2.27M	2.99M	7M	8.53M	13.55M
Days Sales Outstanding	48.98	52.64	48.43	10.28	41.42	53.08	45.2	55.77	47.92	57.07
Inventory	409.78K	348.46K	711.4K	465.31K	746.52K	1.15M	2.05M	3.55M	4.72M	2.75M
Days Inventory Outstanding	167.68	134.79	322.14	334.71	225.32	259.25	323.46	203.65	219.28	123.45
Other Current Assets	0	0	0	-409.58K	0	0	0	1.1M	608.41K	1.12M
Total Non-Current Assets+	233.13K	175.28K	180.5K	2.06M	2.26M	5.34M	11.79M	40.42M	54.87M	54.79M
Property, Plant & Equipment	41.76K	34.94K	63.21K	52.83K	790.2K	1.15M	2.04M	2.22M	3.25M	1.88M
Fixed Asset Turnover	80.75x	157.64x	99.74x	110.51x	14.89x	13.60x	11.82x	20.62x	19.98x	46.10x
Goodwill	0	0	0	0	0	0	0	3.6M	3.6M	3.6M
Intangible Assets	191.37K	140.34K	117.29K	52.27K	1.47M	3.1M	4.73M	31.51M	44.93M	41.01M
Long-Term Investments	0	0	0	1.96M	0	1.1M	5.02M	3.08M	3.08M	8.3M
Other Non-Current Assets	0	0	0	979.98K	0	0	0	0	0	0
Total Assets+	1.39M	2.17M	2.22M	3.04M	11.12M	9.83M	36.4M	61.04M	73.87M	88.09M
Asset Turnover	2.42x	2.54x	2.84x	1.92x	1.06x	1.59x	0.66x	0.75x	0.88x	0.98x
Asset Growth %	-0.07%	0.56%	0.02%	0.37%	2.65%	-0.12%	2.7%	0.68%	0.21%	0.19%
Total Current Liabilities+	1.46M	1.39M	2.12M	404K	2.64M	3.54M	6.02M	12.81M	13.77M	15.29M
Accounts Payable	222.35K	238.23K	225.46K	117.47K	406.17K	494.84K	593.97K	1.43M	2M	1.5M
Days Payables Outstanding	90.99	92.15	102.1	84.5	122.59	111.72	93.8	81.87	93.05	67.25
Short-Term Debt	614.7K	418.1K	1.2M	0	0	0	0	0	580.36K	0
Deferred Revenue (Current)	617.23K	737.98K	13.92K	0	0	0	0	0	1000K	0
Other Current Liabilities	21.41K	-3.72K	13.92K	44.69K	0	0	0	1.16M	-947.68K	0
Current Ratio	0.79x	1.43x	0.96x	2.42x	3.35x	1.27x	4.09x	1.61x	1.38x	2.18x
Quick Ratio	0.51x	1.18x	0.63x	1.27x	3.07x	0.94x	3.75x	1.33x	1.04x	2.00x
Cash Conversion Cycle	125.68	95.28	268.47	260.5	144.15	200.61	274.86	177.55	174.15	113.26
Total Non-Current Liabilities+	1.2M	1.2M	1.43M	1.53M	2.08M	446.09K	222.15K	6.51M	15.52M	33.89M
Long-Term Debt	1.2M	1.2M	0	1.5M	1.5M	0	0	0	9.11M	30.69M
Capital Lease Obligations	3.97K	0	0	0	481.38K	355.8K	222.15K	505.29K	1.74M	1.24M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	25.98K	103.56K	90.29K	0	6M	4.66M	1.96M
Total Liabilities	2.66M	2.59M	2.12M	1.93M	4.72M	3.99M	6.24M	19.32M	29.28M	49.18M
Total Debt+	1.82M	1.62M	1.2M	1.5M	2.1M	481.38K	425.44K	819.22K	11.79M	32.29M
Net Debt	1.64M	784.62K	736.81K	768.15K	-4.51M	26.02K	-18.23M	-8.14M	6.64M	16.41M
Debt / Equity	-	-	11.70x	1.35x	0.33x	0.08x	0.01x	0.02x	0.26x	0.83x
Debt / EBITDA	-	-	5.97x	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	3.66x	-	-	-	-	-	-	-
Interest Coverage	-5.46x	-1.56x	0.95x	-5.80x	-25.87x	-436.73x	-10374.34x	-43.96x	-8.86x	-2.15x
Total Equity+	-1.27M	-423.07K	102.54K	1.11M	6.39M	5.84M	30.15M	41.72M	44.59M	38.91M
Equity Growth %	-0.54%	0.67%	1.24%	9.85%	4.75%	-0.09%	4.16%	0.38%	0.07%	-0.13%
Book Value per Share	-1.19	-0.39	0.05	0.51	3.00	1.02	4.11	5.28	5.39	4.59
Total Shareholders' Equity	-1.27M	-423.07K	102.54K	1.11M	6.61M	6.15M	30.64M	41.83M	44.83M	39.4M
Common Stock	107.27K	109.69K	113.43K	236.65K	3.57K	6.3K	7.68K	8.3K	8.54K	8.75K
Retained Earnings	-46.78M	-47.2M	-46.87M	-47.47M	-2.68M	-7.03M	-15.24M	-23.39M	-28.04M	-37.78M
Treasury Stock	-12.04K	-12.04K	-12.04K	0	0	0	0	0	0	0
Accumulated OCI	-31.48K	-41.33K	-56.95K	-70.12K	0	0	0	0	0	0
Minority Interest	0	0	0	0	-221.69K	-310.39K	-488.4K	-107.56K	-244.26K	-491.61K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.2M	409.25K	-139.86K	277.14K	-2.17M	-4.03M	-4.81M	-5.55M	-3.25M	-23.78K
Operating CF Margin %	-0.36%	0.07%	-0.02%	0.05%	-0.18%	-0.26%	-0.2%	-0.12%	-0.05%	-0%
Operating CF Growth %	0.29%	1.34%	-1.34%	2.98%	-8.82%	-0.86%	-0.19%	-0.15%	0.42%	0.99%
Net Income	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-8.09M	-4.44M	-9.91M
Depreciation & Amortization	60.03K	60.88K	80.65K	83.89K	119.95K	291.37K	596.98K	2.37M	3.68M	4.92M
Stock-Based Compensation	44.58K	813.95K	60.25K	14.87K	0	1.4M	2.67M	2.7M	3.44M	4.44M
Deferred Taxes	0	0	0	0	0	0	0	-5.84M	0	0
Other Non-Cash Items	383.39K	1.01M	-197.62K	87.71K	407.33K	-106.08K	1.1M	2.79M	-2.64M	1.44M
Working Capital Changes	-305.86K	-243.44K	-354.2K	706.11K	141.1K	-1.18M	-1.18M	517.62K	-3.28M	-911.72K
Change in Receivables	20.26K	-503.23K	-64.41K	609.23K	-324.37K	-961.46K	-774.8K	-2.27M	-1.73M	-4.54M
Change in Inventory	-141K	-91.23K	-420.42K	262.89K	-401.65K	-719.81K	-1.15M	-517.27K	-1.55M	1.44M
Change in Payables	33.18K	15.88K	-6.71K	-168K	-84.64K	88.67K	99.13K	-423.75K	575.15K	-471.21K
Cash from Investing+	-5.33K	-3.03K	-85.88K	-8.48K	-1.2M	-2.74M	-5.28M	-3.51M	-10.21M	-6.61M
Capital Expenditures	-5.33K	-3.03K	-85.88K	-8.48K	-182.82K	-544.37K	-171.87K	-147.01K	-265.25K	-205.85K
CapEx % of Revenue	0%	0%	0.01%	0%	0.02%	0.03%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-41.98K	0	-1.52M	-1.1M	-578.59K	-598.45K	650	-1.1M
Cash from Financing+	867.12K	244.93K	-144.55K	-208.1K	9.8M	622.33K	28.3M	-627.35K	9.64M	17.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-46.15K	-32.49K	-223.11K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	750K	496.15K	-190.84K	208.1K	9.8M	39.33K	-642.52K	-627.35K	-958.59K	-2.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.21M	406.22K	-225.74K	268.66K	-3.87M	-5.68M	-5.56M	-6.3M	-3.51M	-253.08K
FCF Margin %	-0.36%	0.07%	-0.04%	0.05%	-0.33%	-0.36%	-0.23%	-0.14%	-0.05%	-0%
FCF Growth %	0.29%	1.34%	-1.56%	2.19%	-15.41%	-0.47%	0.02%	-0.13%	0.44%	0.93%
FCF per Share	-1.13	0.37	-0.11	0.12	-1.82	-0.99	-0.76	-0.80	-0.42	-0.03
FCF Conversion (FCF/Net Income)	0.90x	-0.98x	-0.42x	-0.46x	0.77x	0.93x	0.61x	0.70x	0.75x	0.00x
Interest Paid	0	0	0	0	43.98K	0	711	206	283.95K	1.58M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	323.11%	-98.89%	-75%	-71.23%	-44.02%	-22.09%	-9.97%	-23.15%
Return on Invested Capital (ROIC)	-230.93%	-55.83%	15.04%	-27.68%	-109.32%	-97.5%	-62.19%	-41.26%	-7.45%	-9.45%
Gross Margin	73.55%	82.87%	87.22%	91.31%	89.72%	89.63%	90.43%	86.12%	87.92%	90.61%
Net Margin	-39.75%	-7.55%	5.25%	-10.29%	-23.92%	-27.95%	-32.81%	-17.31%	-6.62%	-11.15%
Debt / Equity	-	-	11.70x	1.35x	0.33x	0.08x	0.01x	0.02x	0.26x	0.83x
Interest Coverage	-5.46x	-1.56x	0.95x	-5.80x	-25.87x	-436.73x	-10374.34x	-43.96x	-8.86x	-2.15x
FCF Conversion	0.90x	-0.98x	-0.42x	-0.46x	0.77x	0.93x	0.61x	0.70x	0.75x	0.00x
Revenue Growth	28.09%	63.33%	14.47%	-7.41%	101.56%	32.47%	54.9%	89.87%	41.77%	33.36%

Revenue by Segment

	2020	2021	2022	2023
Royalty	-	-	-	201K
Royalty Growth	-	-	-	-
Royalty Revenue	201K	201K	201K	-
Royalty Revenue Growth	-	0.00%	0.00%	-
Product Sales Revenue	15.39M	-	-	-
Product Sales Revenue Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sanara MedTech Inc. (SMTI) reported $101.9M in revenue for fiscal year 2024. This represents a 4512% increase from $2.2M in 2011.

Sanara MedTech Inc. (SMTI) grew revenue by 33.4% over the past year. This is strong growth.

Sanara MedTech Inc. (SMTI) reported a net loss of $37.5M for fiscal year 2024.

Dividend & Returns

Sanara MedTech Inc. (SMTI) has a return on equity (ROE) of -23.1%. Negative ROE indicates the company is unprofitable.

Sanara MedTech Inc. (SMTI) had negative free cash flow of $0.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Sanara MedTech Inc. (SMTI) 10-Year Financial Performance & Capital Metrics

SMTI • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesAdvanced Wound Care

Revenue $87M +33.4%
EBITDA -$2M -231.8%
Net Income -$10M -124.6%
EPS (Diluted) -1.14 -119.2%
Gross Margin 90.61% +3.1%
EBITDA Margin -2.07% -148.8%
Operating Margin -7.75% -19.5%
Net Margin -11.15% -68.4%
ROE -23.15% -132.1%
ROIC -9.45% -26.8%
Debt/Equity 0.83 +213.7%
Interest Coverage -2.15 +75.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 49.1%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y41.82%

5Y49.09%

3Y53.12%

TTM30.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-348.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM26.1%

ROCE

10Y Avg-52.43%

5Y Avg-31.64%

3Y Avg-16.58%

Latest-10.11%

Peer Comparison

Advanced Wound Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
NEPHNephros, Inc.	46.54M	4.38	625.71	-0.53%	8.26%	14.8%	0.16
NXGLNEXGEL, Inc.	14.17M	1.74	-3.48	112.47%	-24.69%	-51.65%	0.46
SMTISanara MedTech Inc.	212.4M	23.77	-20.85	33.36%	-36.79%	-6.11%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.37M	5.51M	6.3M	5.84M	11.77M	15.59M	24.14M	45.84M	64.99M	86.67M
Revenue Growth %	0.28%	0.63%	0.14%	-0.07%	1.02%	0.32%	0.55%	0.9%	0.42%	0.33%
Cost of Goods Sold+	891.97K	943.58K	806.04K	507.42K	1.21M	1.62M	2.31M	6.36M	7.85M	8.14M
COGS % of Revenue	0.26%	0.17%	0.13%	0.09%	0.1%	0.1%	0.1%	0.14%	0.12%	0.09%
Gross Profit+	2.48M	4.56M	5.5M	5.33M	10.56M	13.97M	21.83M	39.48M	57.14M	78.53M
Gross Margin %	0.74%	0.83%	0.87%	0.91%	0.9%	0.9%	0.9%	0.86%	0.88%	0.91%
Gross Profit Growth %	0.36%	0.84%	0.2%	-0.03%	0.98%	0.32%	0.56%	0.81%	0.45%	0.37%
Operating Expenses+	3.45M	4.84M	5.36M	5.82M	13.3M	19M	29.21M	52M	61.35M	85.25M
OpEx % of Revenue	1.02%	0.88%	0.85%	1%	1.13%	1.22%	1.21%	1.13%	0.94%	0.98%
Selling, General & Admin	3.39M	4.76M	5.28M	5.74M	13.07M	18.67M	28.05M	45.98M	56.99M	76.56M
SG&A % of Revenue	1%	0.87%	0.84%	0.98%	1.11%	1.2%	1.16%	1%	0.88%	0.88%
Research & Development	0	0	0	0	0	40.19K	558.7K	3.37M	4.13M	5.7M
R&D % of Revenue	-	-	-	-	-	0%	0.02%	0.07%	0.06%	0.07%
Other Operating Expenses	60.03K	21	125	-22.08K	229.95K	291.37K	596.98K	2.66M	225.13K	2.98M
Operating Income+	-964.98K	-272.13K	120.44K	-501.86K	-2.74M	-5.03M	-7.38M	-12.52M	-4.22M	-6.72M
Operating Margin %	-0.29%	-0.05%	0.02%	-0.09%	-0.23%	-0.32%	-0.31%	-0.27%	-0.06%	-0.08%
Operating Income Growth %	0.53%	0.72%	1.44%	-5.17%	-4.46%	-0.84%	-0.47%	-0.7%	0.66%	-0.59%
EBITDA+	-904.95K	-211.25K	201.09K	-444.92K	-2.62M	-4.74M	-6.6M	-10.15M	-540.13K	-1.79M
EBITDA Margin %	-0.27%	-0.04%	0.03%	-0.08%	-0.22%	-0.3%	-0.27%	-0.22%	-0.01%	-0.02%
EBITDA Growth %	0.55%	0.77%	1.95%	-3.21%	-4.89%	-0.81%	-0.39%	-0.54%	0.95%	-2.32%
D&A (Non-Cash Add-back)	60.03K	60.88K	80.65K	56.94K	119.95K	291.37K	771.93K	2.37M	3.68M	4.92M
EBIT	-1.16M	-241.25K	458.13K	-513.99K	-2.73M	-4.43M	-7.99M	-13.94M	-3.96M	-6.78M
Net Interest Income+	-176.89K	-174.49K	-126.83K	-86.59K	-105.92K	-11.53K	-711	0	-475.78K	-3.11M
Interest Income	0	0	0	0	0	0	0	284.75K	0	21.98K
Interest Expense	176.89K	174.49K	126.83K	86.59K	105.92K	11.53K	711	284.75K	475.78K	3.13M
Other Income/Expense	-375.47K	-143.61K	210.87K	-98.71K	-95.72K	589.47K	-617.64K	-1.42M	-224.75K	-3.2M
Pretax Income+	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-13.94M	-4.44M	-9.91M
Pretax Margin %	-0.4%	-0.08%	0.05%	-0.1%	-0.24%	-0.29%	-0.33%	-0.3%	-0.07%	-0.11%
Income Tax+	0	0	0	0	0	0	0	-5.84M	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.99%	0.98%	0.99%	0.57%	0.97%	0.98%
Net Income+	-1.34M	-415.75K	331.31K	-600.57K	-2.81M	-4.36M	-7.92M	-7.94M	-4.3M	-9.66M
Net Margin %	-0.4%	-0.08%	0.05%	-0.1%	-0.24%	-0.28%	-0.33%	-0.17%	-0.07%	-0.11%
Net Income Growth %	0.41%	0.69%	1.8%	-2.81%	-3.69%	-0.55%	-0.82%	-0%	0.46%	-1.25%
Net Income (Continuing)	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-8.09M	-4.44M	-9.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	-221.69K	-310.39K	-488.4K	-107.56K	-244.26K	-491.61K
EPS (Diluted)+	-1.25	-0.38	0.09	-0.28	-1.37	-0.76	-1.08	-1.00	-0.52	-1.14
EPS Growth %	0.42%	0.7%	1.24%	-4.04%	-3.89%	0.45%	-0.42%	0.07%	0.48%	-1.19%
EPS (Basic)	-1.26	-0.38	0.17	-0.28	-1.37	-0.76	-1.08	-1.00	-0.52	-1.14
Diluted Shares Outstanding	1.07M	1.1M	2.09M	2.17M	2.13M	5.73M	7.34M	7.91M	8.28M	8.48M
Basic Shares Outstanding	1.07M	1.09M	1.11M	2.17M	2.13M	5.73M	7.34M	7.91M	8.28M	8.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.16M	2M	2.04M	978.48K	8.86M	4.48M	24.61M	20.62M	19.01M	33.31M
Cash & Short-Term Investments	182.34K	833.48K	463.19K	731.85K	6.61M	455.37K	18.65M	8.96M	5.15M	15.88M
Cash Only	182.34K	833.48K	463.19K	731.85K	6.61M	455.37K	18.65M	8.96M	5.15M	15.88M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	452.55K	794.29K	836.5K	164.46K	1.34M	2.27M	2.99M	7M	8.53M	13.55M
Days Sales Outstanding	48.98	52.64	48.43	10.28	41.42	53.08	45.2	55.77	47.92	57.07
Inventory	409.78K	348.46K	711.4K	465.31K	746.52K	1.15M	2.05M	3.55M	4.72M	2.75M
Days Inventory Outstanding	167.68	134.79	322.14	334.71	225.32	259.25	323.46	203.65	219.28	123.45
Other Current Assets	0	0	0	-409.58K	0	0	0	1.1M	608.41K	1.12M
Total Non-Current Assets+	233.13K	175.28K	180.5K	2.06M	2.26M	5.34M	11.79M	40.42M	54.87M	54.79M
Property, Plant & Equipment	41.76K	34.94K	63.21K	52.83K	790.2K	1.15M	2.04M	2.22M	3.25M	1.88M
Fixed Asset Turnover	80.75x	157.64x	99.74x	110.51x	14.89x	13.60x	11.82x	20.62x	19.98x	46.10x
Goodwill	0	0	0	0	0	0	0	3.6M	3.6M	3.6M
Intangible Assets	191.37K	140.34K	117.29K	52.27K	1.47M	3.1M	4.73M	31.51M	44.93M	41.01M
Long-Term Investments	0	0	0	1.96M	0	1.1M	5.02M	3.08M	3.08M	8.3M
Other Non-Current Assets	0	0	0	979.98K	0	0	0	0	0	0
Total Assets+	1.39M	2.17M	2.22M	3.04M	11.12M	9.83M	36.4M	61.04M	73.87M	88.09M
Asset Turnover	2.42x	2.54x	2.84x	1.92x	1.06x	1.59x	0.66x	0.75x	0.88x	0.98x
Asset Growth %	-0.07%	0.56%	0.02%	0.37%	2.65%	-0.12%	2.7%	0.68%	0.21%	0.19%
Total Current Liabilities+	1.46M	1.39M	2.12M	404K	2.64M	3.54M	6.02M	12.81M	13.77M	15.29M
Accounts Payable	222.35K	238.23K	225.46K	117.47K	406.17K	494.84K	593.97K	1.43M	2M	1.5M
Days Payables Outstanding	90.99	92.15	102.1	84.5	122.59	111.72	93.8	81.87	93.05	67.25
Short-Term Debt	614.7K	418.1K	1.2M	0	0	0	0	0	580.36K	0
Deferred Revenue (Current)	617.23K	737.98K	13.92K	0	0	0	0	0	1000K	0
Other Current Liabilities	21.41K	-3.72K	13.92K	44.69K	0	0	0	1.16M	-947.68K	0
Current Ratio	0.79x	1.43x	0.96x	2.42x	3.35x	1.27x	4.09x	1.61x	1.38x	2.18x
Quick Ratio	0.51x	1.18x	0.63x	1.27x	3.07x	0.94x	3.75x	1.33x	1.04x	2.00x
Cash Conversion Cycle	125.68	95.28	268.47	260.5	144.15	200.61	274.86	177.55	174.15	113.26
Total Non-Current Liabilities+	1.2M	1.2M	1.43M	1.53M	2.08M	446.09K	222.15K	6.51M	15.52M	33.89M
Long-Term Debt	1.2M	1.2M	0	1.5M	1.5M	0	0	0	9.11M	30.69M
Capital Lease Obligations	3.97K	0	0	0	481.38K	355.8K	222.15K	505.29K	1.74M	1.24M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	25.98K	103.56K	90.29K	0	6M	4.66M	1.96M
Total Liabilities	2.66M	2.59M	2.12M	1.93M	4.72M	3.99M	6.24M	19.32M	29.28M	49.18M
Total Debt+	1.82M	1.62M	1.2M	1.5M	2.1M	481.38K	425.44K	819.22K	11.79M	32.29M
Net Debt	1.64M	784.62K	736.81K	768.15K	-4.51M	26.02K	-18.23M	-8.14M	6.64M	16.41M
Debt / Equity	-	-	11.70x	1.35x	0.33x	0.08x	0.01x	0.02x	0.26x	0.83x
Debt / EBITDA	-	-	5.97x	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	3.66x	-	-	-	-	-	-	-
Interest Coverage	-5.46x	-1.56x	0.95x	-5.80x	-25.87x	-436.73x	-10374.34x	-43.96x	-8.86x	-2.15x
Total Equity+	-1.27M	-423.07K	102.54K	1.11M	6.39M	5.84M	30.15M	41.72M	44.59M	38.91M
Equity Growth %	-0.54%	0.67%	1.24%	9.85%	4.75%	-0.09%	4.16%	0.38%	0.07%	-0.13%
Book Value per Share	-1.19	-0.39	0.05	0.51	3.00	1.02	4.11	5.28	5.39	4.59
Total Shareholders' Equity	-1.27M	-423.07K	102.54K	1.11M	6.61M	6.15M	30.64M	41.83M	44.83M	39.4M
Common Stock	107.27K	109.69K	113.43K	236.65K	3.57K	6.3K	7.68K	8.3K	8.54K	8.75K
Retained Earnings	-46.78M	-47.2M	-46.87M	-47.47M	-2.68M	-7.03M	-15.24M	-23.39M	-28.04M	-37.78M
Treasury Stock	-12.04K	-12.04K	-12.04K	0	0	0	0	0	0	0
Accumulated OCI	-31.48K	-41.33K	-56.95K	-70.12K	0	0	0	0	0	0
Minority Interest	0	0	0	0	-221.69K	-310.39K	-488.4K	-107.56K	-244.26K	-491.61K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.2M	409.25K	-139.86K	277.14K	-2.17M	-4.03M	-4.81M	-5.55M	-3.25M	-23.78K
Operating CF Margin %	-0.36%	0.07%	-0.02%	0.05%	-0.18%	-0.26%	-0.2%	-0.12%	-0.05%	-0%
Operating CF Growth %	0.29%	1.34%	-1.34%	2.98%	-8.82%	-0.86%	-0.19%	-0.15%	0.42%	0.99%
Net Income	-1.34M	-415.75K	331.31K	-600.57K	-2.84M	-4.45M	-7.99M	-8.09M	-4.44M	-9.91M
Depreciation & Amortization	60.03K	60.88K	80.65K	83.89K	119.95K	291.37K	596.98K	2.37M	3.68M	4.92M
Stock-Based Compensation	44.58K	813.95K	60.25K	14.87K	0	1.4M	2.67M	2.7M	3.44M	4.44M
Deferred Taxes	0	0	0	0	0	0	0	-5.84M	0	0
Other Non-Cash Items	383.39K	1.01M	-197.62K	87.71K	407.33K	-106.08K	1.1M	2.79M	-2.64M	1.44M
Working Capital Changes	-305.86K	-243.44K	-354.2K	706.11K	141.1K	-1.18M	-1.18M	517.62K	-3.28M	-911.72K
Change in Receivables	20.26K	-503.23K	-64.41K	609.23K	-324.37K	-961.46K	-774.8K	-2.27M	-1.73M	-4.54M
Change in Inventory	-141K	-91.23K	-420.42K	262.89K	-401.65K	-719.81K	-1.15M	-517.27K	-1.55M	1.44M
Change in Payables	33.18K	15.88K	-6.71K	-168K	-84.64K	88.67K	99.13K	-423.75K	575.15K	-471.21K
Cash from Investing+	-5.33K	-3.03K	-85.88K	-8.48K	-1.2M	-2.74M	-5.28M	-3.51M	-10.21M	-6.61M
Capital Expenditures	-5.33K	-3.03K	-85.88K	-8.48K	-182.82K	-544.37K	-171.87K	-147.01K	-265.25K	-205.85K
CapEx % of Revenue	0%	0%	0.01%	0%	0.02%	0.03%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-41.98K	0	-1.52M	-1.1M	-578.59K	-598.45K	650	-1.1M
Cash from Financing+	867.12K	244.93K	-144.55K	-208.1K	9.8M	622.33K	28.3M	-627.35K	9.64M	17.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-46.15K	-32.49K	-223.11K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	750K	496.15K	-190.84K	208.1K	9.8M	39.33K	-642.52K	-627.35K	-958.59K	-2.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.21M	406.22K	-225.74K	268.66K	-3.87M	-5.68M	-5.56M	-6.3M	-3.51M	-253.08K
FCF Margin %	-0.36%	0.07%	-0.04%	0.05%	-0.33%	-0.36%	-0.23%	-0.14%	-0.05%	-0%
FCF Growth %	0.29%	1.34%	-1.56%	2.19%	-15.41%	-0.47%	0.02%	-0.13%	0.44%	0.93%
FCF per Share	-1.13	0.37	-0.11	0.12	-1.82	-0.99	-0.76	-0.80	-0.42	-0.03
FCF Conversion (FCF/Net Income)	0.90x	-0.98x	-0.42x	-0.46x	0.77x	0.93x	0.61x	0.70x	0.75x	0.00x
Interest Paid	0	0	0	0	43.98K	0	711	206	283.95K	1.58M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	323.11%	-98.89%	-75%	-71.23%	-44.02%	-22.09%	-9.97%	-23.15%
Return on Invested Capital (ROIC)	-230.93%	-55.83%	15.04%	-27.68%	-109.32%	-97.5%	-62.19%	-41.26%	-7.45%	-9.45%
Gross Margin	73.55%	82.87%	87.22%	91.31%	89.72%	89.63%	90.43%	86.12%	87.92%	90.61%
Net Margin	-39.75%	-7.55%	5.25%	-10.29%	-23.92%	-27.95%	-32.81%	-17.31%	-6.62%	-11.15%
Debt / Equity	-	-	11.70x	1.35x	0.33x	0.08x	0.01x	0.02x	0.26x	0.83x
Interest Coverage	-5.46x	-1.56x	0.95x	-5.80x	-25.87x	-436.73x	-10374.34x	-43.96x	-8.86x	-2.15x
FCF Conversion	0.90x	-0.98x	-0.42x	-0.46x	0.77x	0.93x	0.61x	0.70x	0.75x	0.00x
Revenue Growth	28.09%	63.33%	14.47%	-7.41%	101.56%	32.47%	54.9%	89.87%	41.77%	33.36%

Revenue by Segment

	2020	2021	2022	2023
Royalty	-	-	-	201K
Royalty Growth	-	-	-	-
Royalty Revenue	201K	201K	201K	-
Royalty Revenue Growth	-	0.00%	0.00%	-
Product Sales Revenue	15.39M	-	-	-
Product Sales Revenue Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sanara MedTech Inc. (SMTI) reported $101.9M in revenue for fiscal year 2024. This represents a 4512% increase from $2.2M in 2011.

Sanara MedTech Inc. (SMTI) grew revenue by 33.4% over the past year. This is strong growth.

Sanara MedTech Inc. (SMTI) reported a net loss of $37.5M for fiscal year 2024.

Dividend & Returns

Sanara MedTech Inc. (SMTI) has a return on equity (ROE) of -23.1%. Negative ROE indicates the company is unprofitable.

Sanara MedTech Inc. (SMTI) had negative free cash flow of $0.9M in fiscal year 2024, likely due to heavy capital investments.